• SKYRIZI (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis
  • Approval was based on the pivotal Phase 3 OptIMMize-1 and OptIMMize-2 trials which include a new 55 mg pre-filled syringe to support weight-based dosing for patients weighing less than 40 kg
  • Nearly a third of people living with psoriasis develop symptoms before the age of 18, often getting lesions on highly visible areas2